title: Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelin-1.
abstract: The IC50 values of phosphoramidon, CGS 25015, CGS 26129, thiorphan and benazeprilat for inhibition of endothelin converting enzyme partially purified from porcine aortic endothelial cells were 3.5, 18, 58, > 100 and > 100 microM, respectively. A similar rank order of potency was observed for inhibition of the proendothelin-1 (proET-1) -induced pressor response in the rat where phosphoramidon, CGS 25015, CGS 26129, thiorphan and benazeprilat at 30 mg/kg i.v. produced 65, 57, 27, 12, and 0% inhibition, respectively. A slightly different rank order of potency was obtained in the proET-induced contraction of porcine coronary arteries where IC50 values of < 10, 10-30, 10-30, 30-100 and 30-100 microM were exhibited by CGS 25015, CGS 26129, phosphoramidon, thiorphan and benazeprilat, respectively. These data indicate that the endothelin converting enzymes in the three systems studied are similar, except that phosphoramidon is a slightly more potent inhibitor in the in vitro assay and the in vivo pressor test than in the smooth muscle contraction assay.
authors.affiliation: Pharmaceuticals Division CIBA-GEIGY Corporation, Summit, NJ 07901.
authors.forename: A J
authors.initials: AJ
authors.lastname: Trapani
authors.forename: J L
authors.initials: JL
authors.lastname: Balwierczak
authors.forename: R W
authors.initials: RW
authors.lastname: Lappe
authors.forename: J L
authors.initials: JL
authors.lastname: Stanton
authors.forename: S C
authors.initials: SC
authors.lastname: Graybill
authors.forename: M F
authors.initials: MF
authors.lastname: Hopkins
authors.forename: P
authors.initials: P
authors.lastname: Savage
authors.forename: D M
authors.initials: DM
authors.lastname: Sperbeck
authors.forename: A Y
authors.initials: AY
authors.lastname: Jeng
mesh_terms: D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D001552:Benzazepines / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins / Q000378:metabolism* / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000201:enzymology; D006020:Glycopeptides / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008666:Metalloendopeptidases; D008715:Methionine / Q000031:analogs & derivatives / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011422:Propionates / Q000494:pharmacology; D011498:Protein Precursors / Q000378:metabolism* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013552:Swine; D015244:Thiorphan / Q000494:pharmacology
chemical_list: D001552:Benzazepines; D019332:Endothelin-1; D016232:Endothelins; D006020:Glycopeptides; D011422:Propionates; D011498:Protein Precursors; C093240:proendothelin 1; C086374:CGS 26129; C086373:CGS 25015; D008715:Methionine; D015244:Thiorphan; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D015260:Neprilysin; D000072396:Endothelin-Converting Enzymes; C052133:benazeprilat; C008890:phosphoramidon